So I wouldn't worry about that. Healthcare is not nearly as expensive as US providers make it. Single payer systems aren't perfect either but from my perspective having lived with one my entire life it works fine. I have always gotten the help I need in reasonable time. I also have private options if I want to spend money, and they're far cheaper than private options in the US. But so far I haven't felt any need for it. A colleague was recently diagnosed with testicular cancer, he was admitted for surgery within a few days and back to work in a few weeks. Didn't cost him anything.
And just to reiterate - this is cheaper per capita, just comparing tax costs, than the US system and that's ignoring insurance premiums and copays etc.
How do you think about the nationalisation of generics of existing drugs being detrimental to new drugs' development?
Even if you discover a groundbreaking new antibiotic under current incentives it's going to get fed to pigs in China until it's useless.
Arguably the kinds of antibiotics we need the most are ones with significant side effects; effective enough that they can save humans but with side effects that are severe enough that they are not over-prescribed or fed to livestock.
I don’t think there can be a better example of perverse incentives than this.
What? Absolutely not. The patients would have a very strong incentive to not finish the whole course of treatment.
Do Chinese farms do it more / worse?
Firstly, while pharma collectively spends a lot of money (many, many billions) on drug discovery and development, in the grand scheme of collective global governmental spending, it’s not so very much. If the (e.g.) 20 richest nations got together and shared out the cost according GDP it wouldn’t be too much for them to bear at all.
Secondly, as a race we’re currently very bad at ‘global’ cooperation, especially if it requires ’vision’. Even when there’s a strong incentive to cooperate across borders (like, say, an immediate threat from a global pandemic) we mostly sucked. And even relative success stories coming out of the pandemic, like the development of mRNA vaccines spectacularly quickly, had less to do with global coordination and cooperation than might have been the case. It would be wonderful to start to address this broad topic, and the constant threat from antibiotic resistance would seem like a great place to start, before we get to the stage that any operation brings the threat of death by untreatable infection with it.